Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations.

ABSTRACT: Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee. The purpose of this study was to update those recommendations, especially for the treatment of metastatic or recurrent EGFR-mutated NSCLC. We conducted a literature search of systematic reviews of randomized controlled and nonrandomized trials published between 2018 and 2019 that multiple physicians had reviewed independently. On the basis of those studies and the advice from the Japanese Society of Lung Cancer Expert Panel, we developed updated guidelines according to the Grading of Recommendations, Assessment, Development, and Evaluatio

SUBMITTER: Ninomiya K 

PROVIDER: S-EPMC8474490 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature